DiaGenic, Pfizer Sign Deal for Alzheimer's Biomarker Discovery
December 17, 2010
DiaGenic, Pfizer Sign Deal for Alzheimer's Biomarker Discovery
The firms will use DiaGenic's gene expression technology in a study to identify biomarkers related to patients who progress from mild cognitive impairment to Alzheimer's.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Emerald Logic, King's College London Collaborate on Identifying Alzheimer's Markers
February 5, 2013 / GenomeWeb Daily News - Opko, Bristol-Myers Collaboration to Include Alzheimer's Biomarkers
January 14, 2013 / GenomeWeb Daily News - Australian Team Developing Plasma Protein Panel for Predicting Amyloid Burden in Alzheimer's Patients
May 3, 2013 / ProteoMonitor - OICR to Launch Prostate Marker Clinical Trials with Janssen
April 22, 2013 / GenomeWeb Daily News - Oxford Gene Technology Licenses ICR Prostate Cancer Biomarker Panel
March 13, 2013 / GenomeWeb Daily News